Result of AGM

Verici Dx PLC

28 July 2026

 

Verici Dx plc

("Verici Dx" or the "Company")

Result of Annual General Meeting

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the Annual General Meeting ("AGM") held yesterday, all resolutions were duly passed.

The voting results of the AGM were as follows:

	In Favour		Against		Withheld
Resolution	Votes	%	Votes	%	Votes
1	863,045,026	84.57	157,508,491	15.43	501
2	1,020,180,550	99.96	371,853	0.04	1,615
3	1,020,355,870	99.98	197,647	0.02	501
4	1,017,689,285	99.73	2,758,389	0.27	106,344
5	1,017,257,974	99.69	3,189,109	0.31	106,935

Verici Dx plc	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Singer Capital Markets (Nominated adviser, Joint Broker)		Tel: [phone]
Alex Bond / Russell Cook
Oberon Capital (Joint Broker)	Tel: [phone]
Mike Seabrook / Adam Pollock
Walbrook PR (Media & Investor Relations)	Tel: [phone] or [e-mail]
Alice Woodings / Rachel Broad	Mob: [phone]

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimise therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S.

 

END